<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221412</url>
  </required_header>
  <id_info>
    <org_study_id>CR108653</org_study_id>
    <secondary_id>53718678RSV4001</secondary_id>
    <nct_id>NCT04221412</nct_id>
  </id_info>
  <brief_title>Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants</brief_title>
  <official_title>JNJ-53718678 RSV Pre-Approval Access_Single Patient Access (SPR) for Patients Diagnosed With RSV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Sciences Ireland UC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Sciences Ireland UC</source>
  <brief_summary>
    <textblock>
      The purpose of this pre-approval access program is to provide treatment to immunocompromised
      participants with serious/life-threatening diseases or conditions (Respiratory Syncytial
      Virus [RSV] infection) and to collect the safety data to understand the safety profile of
      JNJ-53718678.
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Respiratory Syncytial Virus</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-53718678</intervention_name>
    <description>JNJ-53718678 will be administered as directed by treating physician.</description>
  </intervention>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Contact</last_name>
    <phone>1-800-JANSSEN (1-800-526-7736)</phone>
    <email>Janssenmedinfo@its.jnj.com</email>
  </overall_contact>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

